References
- 1. Hay CRM. Purchasing factor concentrates in the 21st century through competitive tendering. Haemophilia 2013; 19R5S:660Q7.
- 2. Sharrer I, Ehrlich HJ. Lack of evidence for increased inhibitor incidence in patients switched from plasmaQderived to recombinant factor VIII. Haemophilia 2001; 7: 766.
- 3. Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following widespread introduction of recombinant factor VIII replacement therapy. Transfusion Science 1998; 19R2S: 139T148.10.1016/S0955-3886(98)00024-1
- 4. Rubinger M, Lillicrap D, Rivard GE, et al. A prospective surveillance study of factor VIII inhibitor development in the Canadian hemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia 2008; 14R2S: 281T286.10.1111/j.1365-2516.2007.01634.x
- 5. Collins P, Chalmers E, Hart DP et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: R4th editionS. UK Haemophilia Centre Doctors Organisation. Haematol 2013; 160: 153T170.
- 6. Hay CR, Palmer B, Chalmers E, et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367Q6370.
- 7. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453T459.
- 8. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. ReFacto Phase 3 Study Group. The safety and efficacy of BQdomain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38T49.10.1046/j.1365-2516.2003.00708.x
- 9. Rothschild C, Laurian Y, Satre EP et al. French previously untreated patients with severe haemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thrombosis and Haemostasis 1998; 80: 779 T783.
- 10. Gouw SC, van den Berg HM, le Cessie S et al. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. Journal of Thrombosis and Haemostasis 2007; 5: 1383Q1390.
- 11. Franchini M, Makris M, Santagostino E, et al. NonQthromboticQ, nonQinhibitorQ associated adverse reaction to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand’s disease: a systematic review of prospective studies. Haemophilia 2012; 18R3S: e164T72.10.1111/j.1365-2516.2011.02745.x
- 12. Gouw SC, van der Bom JG, Ljung R et al for the PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe haemophilia A. N Engl J Med 2013; 368: 231T9.